Heal
Clinical software, diagnostics, AI-assisted decisions. Cannot ship without regulator clearance.
The need
Ageing populations and clinical-labour shortages are pushing more care into clinical software, diagnostics, and AI-assisted decision tools. A scan is misread. A treatable condition is caught late. An AI tool is deployed in a clinic without evidence that it works, and a patient pays the price.
Tier 1: device licensing, clinical software clearance, digital health frameworks. Tier 2: clinical safety reporting, AI risk management for medical devices.
The filter
Of those, 3 have effective dates between 2024 and 2030.
Effective dates
In-flight regulations across the four markets, by effective year.
Source: hmm Ventures regulatory dataset.
| Market | Regulation | Tier | Effective |
|---|---|---|---|
| AU | TGA SaMD Regulation Reform | T1 | 2027 |
| JP | PMDA AI Medical Device Fast-Track Expansion | T1 | 2027 |
| SG | HSA Digital Health Regulatory Framework Expansion | T1 | 2027 |
Source: hmm Ventures regulatory dataset.
The cohort
Each mark is one company in the four-market dataset. Highlighted marks are the named exits already on the dataset.
1,269 Biomedical Systems companies. Highlighted marks: named regulated-company acquisitions.
Across the four markets
$240M cash · up to $1.15B total
Status: in flight.
Undisclosed
Status: in flight.
If you allocate capital
A short note on the office, the mandate, and what you have read.
Request a meeting →If you build what people need
Heal, power, move, supply, eat. Read the doctrine before sending a deck.
Tell us more →